Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Amino Bisphosphonates Are Associated with Decreased Mortality Compared to Non-Amino Bisphosphonates in the Treatment of Multiple Myeloma

Marianne Razavi, PhD, Rahul Mhaskar, MPH, Benjamin Djulbegovic, MD

Blood (2018) 132 (Supplement 1): 5638.

https://doi.org/10.1182/blood-2018-99-116976

Published: 2018

Journal Articles

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

Panagiotis Anagnostis, Sofia Vakalopoulou, Dimitrios Christoulas, Spyridon Karras, Athanasios Papatheodorou, Eirini Katodritou, Panagiotis Kokkoris, Vasilia Garipidou, Evangelos Terpos

Blood (2015) 126 (23): 2284.

https://doi.org/10.1182/blood.V126.23.2284.2284

Published: 2015

Journal Articles

Ibandronate and Renal Function In Myeloma Patients

Raoul Bergner, Jochen Breuer, Andreas Sandermann, Michael J. Uppenkamp, Martin Hoffmann

Blood (2010) 116 (21): 5047.

https://doi.org/10.1182/blood.V116.21.5047.5047

Published: 2010

Journal Articles

Comparative Effectiveness of Bisphoshonates In Multiple Myeloma

Rahul Mhaskar, MD, MPH, Jasmina Redzepovic, Keith Wheatley, Otavio Clark, Axel Glasmacher, MD, Branko Miladinovic, PhD, Ambuj Kumar, MD, MPH, Benjamin Djulbegovic, MD, PhD

Blood (2010) 116 (21): 3028.

https://doi.org/10.1182/blood.V116.21.3028.3028

Published: 2010

Journal Articles

Renal Safety of Ibandronate in the Treatment of Myeloma Patients.

Raoul Bergner, Jochen Breuer, Michael J. Uppenkamp, MD, Andreas Sandermann, Martin Hoffmann

Blood (2009) 114 (22): 4943.

https://doi.org/10.1182/blood.V114.22.4943.4943

Published: 2009

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients.

Alessandro Gozzetti, MD, PhD, Giuseppe Martini, MD, Annalisa Avanzati, BS, Beatrice Franci, MD, Elena Marchini, MD, Ranuccio Nuti, MD, Francesco Lauria, MD

Blood (2007) 110 (11): 4828.

https://doi.org/10.1182/blood.V110.11.4828.4828

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

Journal Articles

Open-Label Study of Ibandronate in Elderly Myeloma Patients with Pre-Existing Renal Deterioration.

Dirk Henrich, Raoul Bergner, Martin Hoffmann, Andrea Honecker, Dietmar Nagel, Michael Uppenkamp

Blood (2005) 106 (11): 3459.

https://doi.org/10.1182/blood.V106.11.3459.3459

Published: 2005

Journal Articles

Open-Label Study of Cellular Immunity in Dialysis Patients after Intravenous Ibandronate.

Raoul Bergner, Burkhard Weiss, Martin Hoffman, Dirk Henrich, Michael Uppenkamp

Blood (2005) 106 (11): 3901.

https://doi.org/10.1182/blood.V106.11.3901.3901

Published: 2005

Journal Articles

The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.

Meletios A. Dimopoulos, MD, Efstathios Kastritis, MD, Lia A. Moulopoulos, MD, Ioannis Melakopoulos, MD, Athanasios Anagnostopoulos, MD, Dimitra Gika, George Bozas, MD, Vassiliki Koutsoukou, MD, Aristotelis Bamias, MD

Blood (2005) 106 (11): 637.

https://doi.org/10.1182/blood.V106.11.637.637

Published: 2005

Journal Articles

Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease

Sarah L. Dallas, I. Ross Garrett, Babatunde O. Oyajobi, Mark R. Dallas, Brendan F. Boyce, Frieder Bauss, Jiri Radl, Gregory R. Mundy

Blood (1999) 93 (5): 1697–1706.

https://doi.org/10.1182/blood.V93.5.1697

Published: 1999

NARROW

Amino Bisphosphonates Are Associated with Decreased Mortality Compared to Non-Amino Bisphosphonates in the Treatment of Multiple Myeloma

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

Ibandronate and Renal Function In Myeloma Patients

Comparative Effectiveness of Bisphoshonates In Multiple Myeloma

Renal Safety of Ibandronate in the Treatment of Myeloma Patients.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Open-Label Study of Ibandronate in Elderly Myeloma Patients with Pre-Existing Renal Deterioration.

Open-Label Study of Cellular Immunity in Dialysis Patients after Intravenous Ibandronate.

The Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma Who Receive Biphosphonates Depends on the Type of Biphosphonate.

Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only